Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/16/2025 07:31 PDT] OTLK Expected to Trade Up After Bullish Patterns Develop
• [07/14/2025 13:20 PDT] Outlook Therapeutics, Inc. (NASDAQ:OTLK), Up By 100% ($1.8) From $1.8 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/26/2025 07:19 PDT] OTLK Expected to Trade Up After Bullish Patterns Develop